{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:37:53Z","timestamp":1791581873067,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["11\/129\/245"],"award-info":[{"award-number":["11\/129\/245"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005041","name":"Universit\u00e9 Catholique de Louvain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001285","name":"UCL Institute of Ophthalmology, University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011377","name":"Glaucoma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ogla.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:02:24Z","timestamp":1768993344000},"page":"390-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing the Rate of Retinal Nerve Fiber Layer and Visual Field Loss as Outcomes in Glaucoma Trials"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2804","authenticated-orcid":false,"given":"Giovanni","family":"Montesano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-3902","authenticated-orcid":false,"given":"David P.","family":"Crabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-4847","authenticated-orcid":false,"given":"Giovanni","family":"Ometto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2907-6992","authenticated-orcid":false,"given":"David F.","family":"Garway-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2026.01.010_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.preteyeres.2007.08.001","article-title":"A framework for comparing structural and functional measures of glaucomatous damage","volume":"26","author":"Hood","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ogla.2026.01.010_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1167\/iovs.66.1.32","article-title":"Relationship between intraocular pressure and the true rate of functional and structural progression in the United Kingdom glaucoma treatment study","volume":"66","author":"Montesano","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ogla.2026.01.010_bib4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol (Chicago, Ill : 1960)"},{"key":"10.1016\/j.ogla.2026.01.010_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ogla.2019.01.004","article-title":"Improving the feasibility of glaucoma clinical trials using trend-based visual field progression endpoints","volume":"2","author":"Wu","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2026.01.010_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajo.2021.04.008","article-title":"Improving the power of glaucoma neuroprotection trials using existing visual field data","volume":"229","author":"Montesano","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.12.10.20","article-title":"Validating trend-based end points for neuroprotection trials in glaucoma","volume":"12","author":"Montesano","year":"2023","journal-title":"Translational Vis Sci Technol"},{"key":"10.1016\/j.ogla.2026.01.010_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ophtha.2022.12.025","article-title":"Validation of rates of mean deviation change as clinically relevant end points for glaucoma progression","volume":"130","author":"Medeiros","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.01.010_bib9","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1038\/s41598-023-34009-x","article-title":"A potential primary endpoint for clinical trials in glaucoma neuroprotection","volume":"13","author":"De Moraes","year":"2023","journal-title":"Scientific Rep"},{"key":"10.1016\/j.ogla.2026.01.010_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1442-9071.2012.02770.x","article-title":"\u201cStructure-function relationship\u201d in glaucoma: past thinking and current concepts","volume":"40","author":"Malik","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/iovs.61.13.5","article-title":"Time lag between functional change and loss of retinal nerve fiber layer in glaucoma","volume":"61","author":"Gardiner","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55345-x","article-title":"Sample size requirements of glaucoma clinical trials when using combined optical coherence tomography and visual field endpoints","volume":"9","author":"Wu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ogla.2026.01.010_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.13.4.15","article-title":"Estimating the distribution of true rates of visual field progression in glaucoma","volume":"13","author":"Montesano","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ogla.2026.01.010_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/BF00184085","article-title":"Modelling series of visual fields to detect progression in normal-tension glaucoma","volume":"233","author":"McNaught","year":"1995","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib15","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1167\/iovs.15-16691","article-title":"Global visit effects in point-wise longitudinal modeling of glaucomatous visual fields","volume":"56","author":"Bryan","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib16","first-page":"2654","article-title":"Properties of perimetric threshold estimates from full threshold, SITA standard, and SITA fast strategies","volume":"43","author":"Artes","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib17","first-page":"417","article-title":"Response variability in the visual field: Comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes","volume":"41","author":"Henson","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1167\/iovs.12-10299","article-title":"The repeatability of mean defect with size III and size v standard automated perimetry","volume":"54","author":"Wall","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.11.8.3","article-title":"Long- and short-term variability of perimetry in glaucoma","volume":"11","author":"Gardiner","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ogla.2026.01.010_bib20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ophtha.2023.12.032","article-title":"Progressive changes in the neuroretinal rim and retinal nerve fiber layer in glaucoma: impact of baseline values and floor effects","volume":"131","author":"Tomita","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.01.010_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ajo.2024.07.020","article-title":"Time to glaucoma progression detection by optical coherence tomography and visual field in glaucoma individuals of African descent","volume":"269","author":"Wu","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib22","first-page":"T4","article-title":"Evaluation of visual field and imaging outcomes for glaucoma clinical trials (an American ophthalomological society thesis)","volume":"115","author":"Garway-Heath","year":"2017","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ogla.2026.01.010_bib23","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2017.04.035","article-title":"Evidence-based criteria for assessment of visual field reliability","volume":"124","author":"Yohannan","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.01.010_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ophtha.2023.12.031","article-title":"Short-term detection of fast progressors in glaucoma: the fast progression assessment through clustered evaluation (fast-PACE) study","volume":"131","author":"Medeiros","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.01.010_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/ICU.0b013e32834ff490","article-title":"Clinical trials for glaucoma neuroprotection are not impossible","volume":"23","author":"Quigley","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ogla.2019.01.009","article-title":"Glaucoma neuroprotection trials are practical using visual field outcomes","volume":"2","author":"Quigley","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2026.01.010_bib27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ophtha.2007.08.037","article-title":"Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino eye study","volume":"115","author":"McKean-Cowdin","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.01.010_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/aos.12839","article-title":"Visual impairment and vision-related quality of life in the early manifest glaucoma trial after 20 years of follow-up","volume":"93","author":"Peters","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib29","article-title":"Gradually then suddenly? Decline in vision-related quality of life as glaucoma worsens","volume":"2017","author":"Jones","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib30","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1167\/iovs.11-7895","article-title":"Glaucoma research community and FDA look to the future, II: NEI\/FDA glaucoma clinical trial design and endpoints symposium: measures of structural change and visual function","volume":"52","author":"Weinreb","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.10.12.4","article-title":"Hierarchical censored bayesian analysis of visual field progression","volume":"10","author":"Montesano","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ogla.2026.01.010_bib32","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1167\/iovs.12-11185","article-title":"Robust and censored modeling and prediction of progression in glaucomatous visual fields","volume":"54","author":"Bryan","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib33","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1167\/iovs.11-7976","article-title":"Improved estimates of visual field progression using bayesian linear regression to integrate structural information in patients with ocular hypertension","volume":"53","author":"Russell","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib34","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1167\/iovs.10-7111","article-title":"Combining structural and functional measurements to improve detection of glaucoma progression using bayesian hierarchical models","volume":"52","author":"Medeiros","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.01.010_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/tvst.12.10.10","article-title":"Improving the accuracy and speed of visual field testing in glaucoma with structural information and deep learning","volume":"12","author":"Montesano","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ogla.2026.01.010_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-80481-4","article-title":"Impact of race and ethnicity on glaucoma progression detection by perimetry and optical coherence tomography","volume":"14","author":"Beniz","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ogla.2026.01.010_bib37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archopthalmol.2011.1576","article-title":"Effect of race, age, and axial length on optic nerve head parameters and retinal nerve fiber layer thickness measured by cirrus HD-OCT","volume":"130","author":"Knight","year":"2012","journal-title":"Arch Ophthalmol (Chicago, Ill : 1960)"},{"key":"10.1016\/j.ogla.2026.01.010_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1167\/tvst.7.6.12","article-title":"Effects of age, race, and ethnicity on the optic nerve and peripapillary region using spectral-domain OCT 3D volume scans","volume":"7","author":"Poon","year":"2018","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ogla.2026.01.010_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajo.2019.10.034","article-title":"Comparison of short- and long-term variability in standard perimetry and spectral domain optical coherence tomography in glaucoma","volume":"210","author":"Urata","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.01.010_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.preteyeres.2010.02.001","article-title":"Linking structure and function in glaucoma","volume":"29","author":"Harwerth","year":"2010","journal-title":"Prog Retin Eye Res"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419626000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419626000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:09:52Z","timestamp":1785967792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419626000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589419626000104"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2026.01.010","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the Rate of Retinal Nerve Fiber Layer and Visual Field Loss as Outcomes in Glaucoma Trials","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}